Peptidase

Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer

Retrieved on: 
Thursday, June 3, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Biology, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Prostate cancer, Accurin, Targeted Alpha Therapies (TAT) at Bayer, Prostate Cancer at Bayer, Xofigo® (radium Ra 223 dichloride) Injection, NUBEQA® (darolutamide)3, Bayer, Noria Therapeutics (Noria) / PSMA Therapeutics Inc., TARGETED ALPHA THERAPIES (TAT) AT BAYER, PROSTATE CANCER AT BAYER, XOFIGO® (RADIUM RA 223 DICHLORIDE) INJECTION, NUBEQA® (DAROLUTAMIDE)3, BAYER, NORIA THERAPEUTICS (NORIA) / PSMA THERAPEUTICS INC.

Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.

Key Points: 
  • Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.
  • Prostate cancer is the second most commonly diagnosed cancer in men1 and a key area of focus for Bayer.
  • About Noria Therapeutics (Noria) / PSMA Therapeutics Inc.
    Noria is a research and development company managed by experienced radiopharmaceutical development leaders and focused on the development of novel targeted alpha therapeutics and theranostic agents.
  • PSMA Therapeutics Inc. is a subsidiary of Noria to advance the platform of prostate-specific membrane antigen (PSMA) targeting radiotherapeutics.

DGAP-News: Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United States

Retrieved on: 
Thursday, June 3, 2021
Branches of biology, Nuclear medicine, Medicine, Radiation therapy, Medicinal radiochemistry, Medical imaging, Medical physics, Glutamate carboxypeptidase II, Peptidase, Prostate cancer, Eckert, Positron emission tomography, Eckert & Ziegler, Telix Pharmaceuticals, Illuccix(R), ECKERT & ZIEGLER, TELIX PHARMACEUTICALS, ILLUCCIX(R)

Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate closely in the commercialization of GalliaPharm(R) (68Ge/68Ga Generator) and investigational product Illuccix(R) (Kit for the preparation of Ga-68 PSMA-11 injection) in the United States.

Key Points: 
  • Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate closely in the commercialization of GalliaPharm(R) (68Ge/68Ga Generator) and investigational product Illuccix(R) (Kit for the preparation of Ga-68 PSMA-11 injection) in the United States.
  • Illuccix(R) is a preparation for imaging prostate cancer by positron emission tomography (PET) and is currently under review for regulatory approval in the United States and multiple markets worldwide.
  • Eckert & Ziegler and Telix will expand their existing collaboration to further develop access to Ga-68 supply in the United States.
  • "We are pleased to have Telix as a partner and to be able to jointly provide leading edge diagnostic products to prostate cancer patients in the USA."

First Patient Dosed in Japanese Prostate Cancer Imaging Study

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Biology, Prostate cancer, Declan G. Murphy, Prostate cancer screening

The study will enroll ten patients with advanced prostate cancer and is the first clinical evaluation of gallium-based PSMA imaging in Japan.

Key Points: 
  • The study will enroll ten patients with advanced prostate cancer and is the first clinical evaluation of gallium-based PSMA imaging in Japan.
  • The objective is to obtain safety data in a representative Japanese patient population, and to demonstrate that the targeting and biodistribution of TLX591-CDx in Japanese patients is consistent with international experience.
  • Anri Inaki MD PhD, Principal Investigator of the study, said, The development of PSMA prostate imaging in Japan has been eagerly awaited by prostate cancer patients and the urology and nuclear medicine community.
  • Dosing the first patient represents a significant first step for the Japanese domestic medicine community to deliver innovative benefits to Japanese prostate cancer patients.

DGAP-News: SphingoTec Accelerates Growth with Direct Sales

Retrieved on: 
Thursday, May 20, 2021
Branches of biology, Biology, Biomarkers, Life sciences, Biotechnology, Chemical pathology, Medical signs, Dipeptidyl peptidase, Peptidase, DPP3, DPP, Adrenomedullin

b'The issuer is solely responsible for the content of this announcement.\nHennigsdorf/Berlin, Germany, May 20, 2021 - Diagnostics company SphingoTec GmbH ("SphingoTec") announces an expansion of its go-to-market strategy to scale its sales in Germany by creating a direct sales force for its integrated diagnostic solutions.

Key Points: 
  • b'The issuer is solely responsible for the content of this announcement.\nHennigsdorf/Berlin, Germany, May 20, 2021 - Diagnostics company SphingoTec GmbH ("SphingoTec") announces an expansion of its go-to-market strategy to scale its sales in Germany by creating a direct sales force for its integrated diagnostic solutions.
  • SphingoTec will sell directly to healthcare providers its Nexus IB10 point of care platform together with a broad portfolio of assays.
  • The innovative biomarkers include the kidney function biomarker Proenkephalin (penKid), the endothelial function biomarker bioactive Adrenomedullin (bio-ADM), and the cardiac depression biomarker Dipeptidyl Peptidase 3 (DPP3).\nTo drive growth in the German healthcare market, SphingoTec has appointed Steffen Hohmann to lead the direct sales efforts in Germany.
  • It enables SphingoTec to serve the critical care community\'s needs better and help improve care for critically ill patients.

Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Prostate cancer, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, MCRPC

b'MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a Phase III clinical trial of the Company\xe2\x80\x99s PSMA1 targeted prostate cancer therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients with advanced metastatic castrate-resistant prostate cancer (mCRPC).\nThe Phase III \xe2\x80\x9cProstACT\xe2\x80\x9d trial is an international, multi-centre, randomised controlled trial (RCT) in patients with PSMA-expressing mCRPC, experiencing disease progression following prior treatment with a novel androgen axis drug (NAAD).

Key Points: 
  • b'MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a Phase III clinical trial of the Company\xe2\x80\x99s PSMA1 targeted prostate cancer therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients with advanced metastatic castrate-resistant prostate cancer (mCRPC).\nThe Phase III \xe2\x80\x9cProstACT\xe2\x80\x9d trial is an international, multi-centre, randomised controlled trial (RCT) in patients with PSMA-expressing mCRPC, experiencing disease progression following prior treatment with a novel androgen axis drug (NAAD).
  • The ProstACT trial will enrol approximately 390 patients and incorporates patient selection using 68Ga-PSMA imaging with TLX591-CDx (Illuccix\xc2\xae).
  • The trial will compare standard of care therapy alone versus standard of care therapy plus TLX591, with a primary endpoint of radiographic progression-free survival (rPFS).
  • ProstACT builds on a significant body of clinical data for TLX5912, which to date has been studied in over 200 patients with advanced prostate cancer, across five previous studies.

Sunshine Biopharma Upgrades COVID-19 Provisional Patent Application to Full PCT Application

Retrieved on: 
Tuesday, May 4, 2021
3C-like protease, Sarbecovirus, Peptidase, Virology, NSP5, Protease, Branches of biology, POL, Cysteine protease, Proteins, Severe acute respiratory syndrome–related coronavirus, GC376

Sunshine had originally filed a provisional patent application covering the COVID-19 treatment on May 22, 2020.

Key Points: 
  • Sunshine had originally filed a provisional patent application covering the COVID-19 treatment on May 22, 2020.
  • SARS-CoV-2 produces several functional proteins in infected human cells by cleaving them from two overlapping viral polyproteins, pp1a and pp1ab.
  • One of these functional proteins is a cysteine protease referred to as the main protease, Mpro (also called 3CLpro and nsp5).
  • Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4.

The NOBLE Registry – An International Collaboration to Develop iPSMA SPECT Imaging for Prostate Cancer

Retrieved on: 
Tuesday, April 20, 2021
Branches of biology, Medical physics, Medicine, Neuroimaging, Medical specialties, Radiobiology, Radiation therapy, Glutamate carboxypeptidase II, Peptidase, Single-photon emission computed tomography, Emission computed tomography, Positron emission tomography

The NOBLE (Nobody Left Behind) Registry aims to demonstrate that PSMA single photon emission computed tomography (PSMA SPECT), a diagnostic imaging technology widely available in healthcare facilities throughout the world,4 is a cost-effective and viable alternative.

Key Points: 
  • The NOBLE (Nobody Left Behind) Registry aims to demonstrate that PSMA single photon emission computed tomography (PSMA SPECT), a diagnostic imaging technology widely available in healthcare facilities throughout the world,4 is a cost-effective and viable alternative.
  • \xe2\x80\x9cHowever, millions of men do not have access to PET imaging.
  • For this reason, it is our aspiration to develop a powerful, affordable, and widely available alternative imaging tool by using iPSMA SPECT technology.\xe2\x80\x9d\n\xe2\x80\x9cIntroducing PSMA has been difficult and exciting for the team at Ibadan.
  • When I think of the opportunities for prostate cancer research and management without PET, I am motivated to get past the challenges.

Nemysis Ltd Strengthens Its Scientific Advisory Board With Nutritional and Pharmaceutical Solutions Expert, Linda Cavaletti

Retrieved on: 
Friday, April 23, 2021
Peptidase, Trypsin, Endopeptidase, Cavaletti, Chymotrypsin

I look forward to working with the team over the coming years to build a broad-based, world-class company.

Key Points: 
  • I look forward to working with the team over the coming years to build a broad-based, world-class company.
  • "\n"I am personally very pleased to welcome such an outstanding scientist as an advisor to Nemysis," said Danilo Casadei-Massari, Chairman of the Board.
  • "No doubt Linda Cavaletti\'s expertise will contribute to increasing the value of Nemysis\'s current and future assets.
  • Safety and efficacy have been demonstrated in controlled-repeat-dose clinical trials.\nNemysis\'s novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant.

Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials

Retrieved on: 
Tuesday, April 20, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Branches of biology, Cancer, Clinical medicine, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Cancer immunotherapy, Prostate cancer, Chemotherapy

Janux\xe2\x80\x99s proprietary Tumor Activated T Cell Engager (TRACTr) technology is designed to overcome specific limitations of current T cell immuno-oncology therapies.

Key Points: 
  • Janux\xe2\x80\x99s proprietary Tumor Activated T Cell Engager (TRACTr) technology is designed to overcome specific limitations of current T cell immuno-oncology therapies.
  • Although previous therapies utilizing other technologies have displayed substantial anti-tumor activity, they have been constrained by dose-limiting toxicities, poor pharmacokinetic profiles, and attenuated efficacy.
  • Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations.
  • Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2).

Hoag Launches First In United States Myeloma Imaging Trial and First in Orange County Prostate Cancer Molecular Therapy Trial

Retrieved on: 
Monday, April 19, 2021
Branches of biology, Health sciences, Life sciences, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Prostate cancer, Molecular imaging, Therapy

b'NEWPORT BEACH, Calif., April 19, 2021 /PRNewswire/ --Hoag Family Cancer Institute announced the opening of two additional molecular imaging and therapy trials, the first to be offered in Orange County and in the United States.

Key Points: 
  • b'NEWPORT BEACH, Calif., April 19, 2021 /PRNewswire/ --Hoag Family Cancer Institute announced the opening of two additional molecular imaging and therapy trials, the first to be offered in Orange County and in the United States.
  • Hoag\'s Molecular Imaging & Therapy Program is helping to pioneer the most sensitive imaging and therapy methods to date to advance research and applications of molecular imaging and therapy.
  • The trial will test the use of a highly targeted molecular imaging agent in the earliest detection and location of a patient\'s myeloma.
  • Ulaner led the Phase 1 arm of the study before coming to Hoag from Memorial Sloan Kettering Cancer Center.\nThe PSMA I-131 trial for prostate cancer will be the county\'s first molecular therapy trial and is funded by Hoag philanthropy.